CCA
MBX

Cygnus Capital Advisors’s MBX Biosciences MBX Stock Holding History

Cygnus Capital Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,800
Closed -$54K – 113
2026
Q1 		$54K Hold
1,800
– – 0.04% 72
2025
Q4 		$57K Buy
+1,800
New +$43.7K 0.04% 65

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Cygnus Capital Advisors's MBX Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of MBX Biosciences (MBX) in Q2 2026, closing a stake of 1,800 shares — an estimated $54K sold.

Cygnus Capital Advisors first reported a position in MBX in Q4 2025 and held it in 2 quarters. The position peaked at $57K in Q4 2025. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining MBX Biosciences position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 1,800 MBX Biosciences shares in Q2 2026, an estimated $54K.
  • Cygnus Capital Advisors first reported a position in MBX Biosciences in Q4 2025 and held it in 2 quarters.
  • Cygnus Capital Advisors's MBX Biosciences position peaked at $57K in Q4 2025.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.